CAV1 and neoplasm: Specifically, female patients expressing high tumour levels of Cav-1 displayed a significantly shorter median survival time compared to male patients expressing high levels of Cav-1 (median survival 90.5 days vs 320 days: HR=3.145, P=0.0000015).